Emerging Treatment Options in Inflammatory Bowel Disease
In Collaboration With
Original Article Reference
This SciPod is a shortened and simplified summary of ‘Emerging Treatment Options in Inflammatory Bowel Disease’, published by Karger Publishers https://doi.org/10.1159/000507782
The complete original works are available at www.karger.com
Share Episode
About this episode
Inflammatory bowel disease (IBD) is a group of gastrointestinal conditions affecting almost 7 million people globally, and this incidence is rising. While treatments have improved over the last century, many patients do not respond sufficiently, especially those with moderate to severe levels of the disease. Novel drugs that restrain the immune system and reduce inflammation are being developed with the hope of improving patient outcomes. Dr Benjamin Misselwitz at Island Hospital of Bern and Bern University and his colleagues have conducted a comprehensive review of the emerging therapies and make recommendations for improving treatment for a wider range of patients.
This work is licensed under a Creative Commons Attribution 4.0 International License. 
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
Related episodes
Dr. Jürgen Gailer | Linking the Blood Chemistry of Metals with Adverse Human Health: New Tools Reveal an Invisible World
Researchers Maryam Doroudian and Jürgen Gailer from the University of Calgary explore what happens when red blood cells rupture and release a zinc-containing enzyme called carbonic anhydrase 1 into the bloodstream, revealing that it remains unexpectedly free and may influence vascular health. Their work also connects to broader research showing how liquid chromatography is transforming our ability to study toxic cadmium and mercury as they move through the body. Together, these studies uncover hidden biochemical processes that shape how environmental pollutants and blood-cell damage affect human health.
Easing the Hardest Moment: How Brain Stimulation Is Transforming Care for People with Opioid Use Disorder
In the world of opioid addiction treatment, the hardest moment often arrives precisely when hope begins to emerge. It is the moment someone chooses to stop using opioids. That decision, courageous and life-changing, almost immediately collides with one of the most punishing physiologic syndromes known in medicine: opioid withdrawal. Withdrawal brings waves of nausea, sweats, shaking, cramps, insomnia, anxiety, and extremely intense cravings. For countless individuals, this moment is a seemingly inescapable stumbling block that can be the undoing of their recovery. They want to stop, they mean to stop, but withdrawal can become an insurmountable barrier.
Dr. Rasha Bayoumi | Decolonizing Global Collaboration: Building Equitable Science Diplomacy
Science diplomacy, meaning the use of scientific collaboration to strengthen international relations and address shared global challenges, has long been hailed as a force for good. Yet, as Dr. Rasha Bayoumi of the University of Birmingham Dubai and her colleagues argue in their Editorial for a special issue in the journal Frontiers in Public Health, this optimism often masks uncomfortable realities. The practice of science diplomacy has too often reproduced the very inequalities it aims to dismantle, operating within frameworks that privilege powerful nations and institutions while marginalizing voices from the Global South.
Lighting the Path: How the GlioLighT Consortium Is Exploring New Ways to Treat Brain Tumours
Across the world, scientists are still trying to answer one of medicine’s most difficult questions: how can we safely and effectively treat brain cancers such as glioma? Despite decades of effort, outcomes for people diagnosed with high-grade glioma remain bleak. Current treatments, including surgery, radiotherapy, and chemotherapy, can slow the disease, but rarely stop it. The GlioLighT consortium, a multidisciplinary European research team funded by the European Innovation Council, has come together to explore a novel approach based on direct light therapy. Being in a very early stage, the project doesn’t promise an immediate cure; instead, it sets out to answer a very fundamental question: can light itself trigger biological processes that might form the basis of a safe and targeted brain tumor therapy?